Literature DB >> 23116323

Long-term treatment acceptance: what is it, and how can it be assessed?

Claire Marant1, Juliette Longin, Rémi Gauchoux, Benoit Arnould, Céderic Spizak, Alexia Marrel, Donald L Patrick, Eric Van Ganse.   

Abstract

BACKGROUND: Understanding the link between patients' beliefs and behavior may help explain their attitude to their treatment. How patients' personal experience of their treatment results in their decision to accept taking it or not and to persist in taking it remains to be explored more thoroughly. Acceptance is hypothesized to be the balance patients establish between their medication's advantages and its disadvantages, based on their personal experience with the medication. Measuring patients' acceptance of their medication is likely to predict their behavior (adherence and persistence) towards their treatment.
OBJECTIVE: Our objective was to develop a generic medication acceptance measure assessing how patients weigh advantages and disadvantages of long-term medications.
METHODS: A literature review was conducted using keywords related to acceptance, perceptions, motivations, and barriers linked to treatment. Exploratory interviews were performed with five pharmacists and 19 patients. Interviews were systematically analyzed in order to complete the initial conceptual model. Questionnaire items were generated for each concept identified, using patients' words. The resulting test version was tested for relevance and comprehension with six patients and revised accordingly; the new version was tested on a second set of five patients and revised to create the pilot version of the questionnaire.
RESULTS: Items generated for each concept identified were organized into six domains: drug characteristics, duration, constraints, side effects, efficacy, and global acceptance of treatment. Except for a few items that were modified or deleted following patients' suggestions and some minor modifications in the answer choices, the questionnaire was globally well accepted, easy to complete, and considered relevant and appropriate by patients. The pilot version of the ACCEPT© questionnaire contains 32 questions divided into the same six domains as the test version.
CONCLUSIONS: The existence of the hypothesized concept of medication acceptance was confirmed. The ACCEPT© questionnaire will allow assessment of the acceptance of a wide range of long-term medications based on patient experience. Further study will examine how well this measure predicts and explains adherence to these medications.

Entities:  

Mesh:

Year:  2012        PMID: 23116323     DOI: 10.2165/11631340-000000000-00000

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  20 in total

Review 1.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

Review 2.  Adherence: a concept analysis.

Authors:  Janice M Bissonnette
Journal:  J Adv Nurs       Date:  2008-09       Impact factor: 3.187

Review 3.  The Medication Adherence Model: a guide for assessing medication taking.

Authors:  Mary Jayne Johnson
Journal:  Res Theory Nurs Pract       Date:  2002       Impact factor: 0.688

4.  Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness.

Authors:  R Horne; J Weinman
Journal:  J Psychosom Res       Date:  1999-12       Impact factor: 3.006

5.  Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis.

Authors:  R Neame; A Hammond
Journal:  Rheumatology (Oxford)       Date:  2005-03-01       Impact factor: 7.580

Review 6.  Core outcome domains for chronic pain clinical trials: IMMPACT recommendations.

Authors:  Dennis C Turk; Robert H Dworkin; Robert R Allen; Nicholas Bellamy; Nancy Brandenburg; Daniel B Carr; Charles Cleeland; Raymond Dionne; John T Farrar; Bradley S Galer; David J Hewitt; Alejandro R Jadad; Nathaniel P Katz; Lynn D Kramer; Donald C Manning; Cynthia G McCormick; Michael P McDermott; Patrick McGrath; Steve Quessy; Bob A Rappaport; James P Robinson; Mike A Royal; Lee Simon; Joseph W Stauffer; Wendy Stein; Jane Tollett; James Witter
Journal:  Pain       Date:  2003-12       Impact factor: 6.961

7.  Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q).

Authors:  Miguel A Ruiz; Antonio Pardo; Javier Rejas; Javier Soto; Fernando Villasante; José L Aranguren
Journal:  Value Health       Date:  2008-05-20       Impact factor: 5.725

Review 8.  Health beliefs, disease severity, and patient adherence: a meta-analysis.

Authors:  M Robin DiMatteo; Kelly B Haskard; Summer L Williams
Journal:  Med Care       Date:  2007-06       Impact factor: 2.983

9.  Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence.

Authors:  Valerie E Stone; Jamie Jordan; Jerry Tolson; Robert Miller; Tom Pilon
Journal:  J Acquir Immune Defic Syndr       Date:  2004-07-01       Impact factor: 3.731

10.  Hormone therapy after the Women's Health Initiative: a qualitative study.

Authors:  Linda M French; Mindy A Smith; Jodi S Holtrop; Margaret Holmes-Rovner
Journal:  BMC Fam Pract       Date:  2006-10-23       Impact factor: 2.497

View more
  4 in total

1.  Item Reduction, Scoring, and First Validation of the ACCEPTance by the Patients of their Treatment (ACCEPT©) Questionnaire.

Authors:  Benoit Arnould; Hélène Gilet; Donald L Patrick; Catherine Acquadro
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

2.  Assessing patients' acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community.

Authors:  Jérémy Lambert; Michael Chekroun; Hélène Gilet; Catherine Acquadro; Benoit Arnould
Journal:  Health Qual Life Outcomes       Date:  2018-07-06       Impact factor: 3.186

3.  Determinants for acceptance of preventive treatment against heart disease - a web-based population survey.

Authors:  Nielsen Jesper Bo; Jarbøl Dorte Ejg; Gyrd-Hansen Dorte; Barfoed Benedicte Marie Lind; Larsen Pia Veldt
Journal:  BMC Public Health       Date:  2014-08-02       Impact factor: 3.295

4.  Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

Authors:  Vasiliki Chounta; Edgar T Overton; Anthony Mills; Susan Swindells; Paul D Benn; Simon Vanveggel; Rodica van Solingen-Ristea; Yuanyuan Wang; Krischan J Hudson; Mark S Shaefer; David A Margolis; Kimberly Y Smith; William R Spreen
Journal:  Patient       Date:  2021-05-31       Impact factor: 3.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.